Company
ResApp Health Ltd
ASX:RAP
ResApp Health Ltd (ASX:RAP) is listed on the Australian Securities Exchange.
31 stories
Hardware & electrical equipment
Technologies in spotlight at TechKnow Invest Roadshow
The technology roadshow will stop by in Sydney on Tuesday, March 19, and in Melbourne on Thursday, March 21.
Hardware & electrical equipment
ResApp Health completes enrolment for Breathe Easy study
The company expects to receive results from three studies this quarter.
Resapp Health signs up for pilot program in Germany and receives Australian government cash rebate
The pilot project will assess the ResAppDx, ResApp’s smartphone application for diagnosing acute respiratory disease.
ResApp Health set to begin U.S. study of its app to diagnose respiratory diseases
An important step towards the commercialisation of ResAppDx in the U.S.
Resapp Health embarking on new study to evaluate efficacy
Study represents another step towards the commercialisation of ResAppDx in the US.
ResApp Health director provides share support through on-market buying
ResApp has adult and paediatric clinical studies underway in the U.S. and Australian.
ResApp Health's shares are being snapped up
ResApp Health is a digital health company with a focus on smartphone solutions.
Resapp Health to restart respiratory app study after enhancing its technology
Doctors Without Borders is not proceeding with its evaluation of the app.
ResApp Health among ASX Volume Leaders as share price splutters
ResApp to restart study after implementing new data gathering procedures.
ResApp Health to restart U.S. study of its app to diagnose respiratory diseases
The company’s app works by analysing the sound of a patient’s cough to provide a diagnosis.
ResApp Health has more cash in the pot ahead of commercialisation strategy
The technology was developed with funding from the Bill and Melinda Gates Foundation.
ResApp Health director buys 1,000,000 shares on-market
ResApp director buys on the dip to support the stock.
ResApp Health is the ASX Volume Leader as investor call breathes in new life
ResApp shares are flying higher following an investor call
ResApp Health the leading ASX % Faller in morning trade on big volume
ResApp has traded over 90 mln shares by 11:30am this morning
ResApp Health's shares in pre-open pending partnership update
The halt will remain in place until Wednesday 10th May 2017.
ResApp Health expands study of app to diagnose pneumonia
The app analyses the sound of a patient’s cough and provide a diagnosis.
ResApp Health extends partnership with Massachusetts General Hospital
ResApp Health (ASX:RAP) has entered into a two-year expanded research collaboration with Massachusetts General Hospital (MGH) in Boston, U.S.
ResApp Health begins U.S. trial of app to diagnose respiratory diseases
ResApp Health (ASX:RAP) has initiated a study in the U.S. to evaluate the efficacy of the ResAppDx app for the diagnosis of childhood pneumonia and other respiratory conditions.
ResApp Health Ltd to begin diagnosis app study in the U.S.
ResApp Health Ltd (ASX:RAP) has received institutional review board approval from the Texas Children’s Hospital in Houston, U.S. for the SMARTCOUGH-C study.
ResApp Health Ltd app to diagnose respiratory diseases from cough sounds
ResApp Health Ltd (ASX:RAP) has received institutional review board approval at the Massachusetts General Hospital in Boston, U.S. for the SMARTCOUGH-C study.